3 Humongous Healthcare Stocks This Week 2-21-14

  • 5,727 views
Uploaded on

3 of the biggest healthcare winners of the week

3 of the biggest healthcare winners of the week

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
5,727
On Slideshare
0
From Embeds
0
Number of Embeds
7

Actions

Shares
Downloads
7
Comments
0
Likes
1

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide
  • http://www.fool.com/investing/general/2014/02/04/why-furiex-pharmaceuticals-inc-shares-furiously-do.aspx
  • http://finance.yahoo.com/news/ohr-pharmaceutical-present-16th-annual-131500941.html
  • http://finance.yahoo.com/news/athenahealth-surges-stronger-expected-4q-181446268.html
  • http://investor.furiex.com/releasedetail.cfm?ReleaseID=822849

Transcript

  • 1. 3 Humongous Health-Care Stocks This Week
  • 2. The Winter Olympics in Sochi, Russia, wasn’t the only place to find big winners this week. Several health-care stocks also deserved gold medals for fantastic performances. Source: Wikimedia Commons.
  • 3. Forest Laboratories (NYSE: FRX) Shares of this drugmaker soared nearly 36% this week.
  • 4. Why did Forest catch on fire? • Specialty pharmaceutical firm Actavis (NYSE: ACT) announced a $25 billion buyout of Forest Labs. • The deal will result in combined revenues of $15 billion. • Expected operating synergies are around $1 billion.
  • 5. China Biologic Products (Nasdaq: CBPO) Shares of the biopharmaceutical company surged almost 33% higher for the week.
  • 6. Why did China Biologic jump a great wall? • No big new announcements from the company this week. • The earnings announcement is still a few weeks away. • The company has bought back shares in recent months.
  • 7. Chelsea Therapeutics (Nasdaq: CHTP) Shares of the biotech climbed nearly 28% this week.
  • 8. Why did Chelsea shares head north? • Northera gained approval from the FDA. • The drug treats neurogenic orthostatic hypotension (NOH), a disorder that affects 80,000 to 150,000 Americans. • Chelsea expects to launch Northera in the second half of 2014.
  • 9. Best pick to stay humongous? • The FDA win for Northera puts Chelsea in a great position. • Additional studies are required since Northera received accelerated approval, but results will likely be positive. • Chelsea appears poised to attract interest from larger partners.
  • 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!